Related Experiment Videos

Coronary atherosclerotic disease burden: an emerging endpoint in progression/regression studies using intravascular

Paul Schoenhagen1, Steven E Nissen

  • 1The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. schoenp1@ccf.org

Current Drug Targets. Cardiovascular & Haematological Disorders
|July 23, 2003
PubMed

Insights

Coronary artery disease (CAD) events often stem from vulnerable plaques. Intravascular ultrasound (IVUS) offers a novel imaging endpoint for studying plaque burden and morphology in clinical trials.

Area of Science:

  • Cardiology
  • Medical Imaging

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality in Western countries.
  • Acute coronary events, such as myocardial infarction (MI), are frequently caused by vulnerable plaque rupture and thrombosis.
  • Vulnerable plaques are often present years before clinical manifestation, posing a challenge for primary prevention trials.

Purpose of the Study:

  • To review the rationale for using coronary plaque imaging as an endpoint in clinical studies.
  • To describe the application of intravascular ultrasound (IVUS) for assessing coronary plaque burden and morphology.

Main Methods:

  • Review of existing literature on CAD, plaque vulnerability, and imaging modalities.
  • Focus on the methodology and application of intravascular ultrasound (IVUS) in serial studies.

Main Results:

  • Vulnerable plaques are prevalent in asymptomatic individuals long before clinical events.
  • Pharmacological studies targeting MI and death require large populations and extended follow-up.
  • In vivo imaging, specifically IVUS, provides a viable alternative endpoint for assessing plaque progression.

Conclusions:

  • Direct observation of coronary plaque using imaging modalities like IVUS can serve as an effective endpoint in clinical trials.
  • IVUS allows for detailed assessment of plaque burden and morphology, aiding in the evaluation of preventative strategies for CAD.

Related Concept Videos